Loading...
•
Jun 30, 2020
Lantheus Q2 2020 Earnings Report
Reported a decrease in revenue compared to the prior year period and completed the acquisition of Progenics Pharmaceuticals, Inc.
Key Takeaways
Lantheus Holdings, Inc. reported a decrease in worldwide revenue of 23.0% compared to the prior year period. The company had a net loss of $7.0 million, or $(0.16) per fully diluted share, as compared to net income of $6.4 million, or $0.16 per fully diluted share for the second quarter of 2019. They completed the acquisition of Progenics in June.
Completed acquisition of Progenics Pharmaceuticals, Inc., adding robust portfolio of oncology therapeutics and diagnostics to pipeline
Worldwide revenue of $66.0 million for the second quarter 2020, representing a decrease of 23.0% from the prior year period
Net loss of $7.0 million for the second quarter 2020, compared to net income of $6.4 million in the prior year period
GAAP diluted EPS of $(0.16) for the second quarter 2020, compared to GAAP diluted EPS of $0.16 in the prior year period; adjusted diluted EPS of $0.10 for the second quarter 2020, compared to adjusted diluted EPS of $0.27 in the prior year period
Forward Guidance
The Company withdrew full year 2020 revenue, revenue growth, and adjusted fully diluted earnings per share guidance as a result of the continued uncertainties surrounding the scope, duration and impacts of the COVID-19 pandemic. Lantheus continues to be unable to provide guidance as to the overall impacts on its operations and financial results during the ongoing pandemic.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...